BioMarin Pharmaceuticals Chief Accounting Officer Brian Mueller has been named interim CFO until a replacement is brought in for outgoing CFO Dan Spiegelman, the company announced.
Mueller, who has spent the majority of his career as an auditor for Arthur Andersen and KPMG, also serves as senior vice president of finance for the San Rafael, Calif.-based company.
Spiegelman is leaving the company "to pursue other interests and spend more time with family," the company said. He will stay on until Sept. 1 in a senior adviser role to assist with the transition of his replacement. He also serves as executive vice president.
Mueller has worked at BioMarin since 2002, rising to group vice president, corporate controller, then in March 2011 to chief accounting officer, the North Bay Business Journal reported. He is also a member of the company’s board of directors and is chairman of the audit committee for another biotech company, Anthera Pharmaceuticals.
The change in CFO won't impact BioMarin's plans to report fourth-quarter and full-year financial results at the end of February, the company said in its announcement.
"Over the last seven and a half years, [Spiegelman] has played an invaluable role in supporting the company's growth," CEO and Chairman Jean-Jacques Bienaimé said in a statement.
"I am confident that [Mueller] in the acting CFO role will help us build on the strong foundation established and seamlessly execute on our business strategies,” Bienaimé said. “[After] 17 years ... at the company, [he] has a deep knowledge of our business, and throughout his career here, has been essential in laying the groundwork for BioMarin's continued long-term success.
At the time of publication, representatives for BioMarin, Spiegelman and Mueller had not responded to requests for comment.